Systematic review finds platelet factor 4 modulates cognitive, immune, and hematopoietic aging through multiple signaling pathways.
This systematic review examined evidence for platelet factor 4 (PF4) in age-related dysfunction across cognitive, immune, and hematopoietic systems. The authors report that PF4 engages CXCR3 and LDLR receptors to activate downstream signaling, with reported effects including reduced hippocampal neuroinflammation, enhanced synaptic plasticity, restored T-cell balance, and preserved hematopoietic stem cell function in aging. Clinical observational studies identified correlations between circulating PF4 levels and conditions including Alzheimer's disease, sarcopenia, stroke, and coronary artery disease.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 2, 2026 · Discovered: Sep 17, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Systematic review
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Modulatory roles of Platelet Factor 4 (PF4) in age-related dysfunction across cognitive, immune, and hematopoietic systems
- Effect size
- —
- Significance
- Not reported
- Journal
- Frontiers in Immunology
- Published
- Sep 2, 2026
Sources
Primary source
- Frontiers in immunology ↗Peer reviewed
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.